I personally like HZNP due to its pipeline and strong growth. The latest quarterly earning showed that its growth was accelerated.
However, interestingly enough, the share did not perform well post earning release. But overall target price from many analysts is in the range of $37-$40 per share.
Even without Depomed acquisition, I still believe that HZNP will continue to grow strongly due to its broad pipeline and its novelty drug for orphan disease.
Risk Reward Ratio calculation
As I mention that most analysts' TP is about $37-40 so I will use $37.
Yesterday (9/17/2018) HZNP share went up significantly with tremendous (Fed minutes did play huge role here) but it did not fade downward like SPX or most of stocks. Hence, signal a pocket buypoint.
Exit at 8% cutloss 28.67
RRR = 0.4
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for Horizon Pharma's (HZNP -1.5%) RAVICTI (glycerol phenylbutyrate) Oral Liquid for use as adjunctive therapy for chronic management of adult and pediatric (greater than two months of age) patients with urea cycle disorders (UCDs).
I still believe that HZNP will outperform its peers even without DEPO deal.
Still waiting for a good entry